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ABSTRACT
Escherichia coli is the most frequent microorgan-
ism involved in urinary tract infection (UTI).
Acute UTI caused by uropathogenic E. coli
(UPEC) can lead to recurrent infection, which
can be deﬁned as either re-infection or relapse.
E. coli strains causing relapse (n = 27) and re-
infection (n = 53) were analysed. In-vitro produc-
tion of bioﬁlm, yersiniabactin and aerobactin was
signiﬁcantly more frequent among strains causing
relapse. Bioﬁlm assays may be helpful in selecting
patients who require a therapeutic approach to
eradicate persistent bioﬁlm-forming E. coli strains
and prevent subsequent relapses.
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Escherichia coli is the most frequent cause of
urinary tract infection (UTI). Uropathogenic E. coli
(UPEC) strains have a number of virulence factors
that increase their ability to colonise and persist in
the urogenital tract [1]. Acute UTI caused by
UPEC can lead to recurrent infection, which is
deﬁned as ‘re-infection’ when it involves a strain
other than that causing the original infection, or as
‘relapse’ when it is caused by the same strain as
that involved in the original UTI. Approximately
25% of women with an episode of acute cystitis
later develop recurrent UTI, which represents a
substantial burden to the healthcare system. Con-
sequently, studies are underway to elucidate the
factors predisposing to recurrent UTI in order to
develop effective methods of prevention and
therapy [2]. In the present study, patients were
followed prospectively for several months in
order to determine the nature of any recurrence.
The E. coli strains isolated were analysed to
determine any possible relationships among re-
lapse ⁄ re-infection, bioﬁlm formation and the pres-
ence of virulence factors.
In total, 43 ambulatory female patients aged
>18 years were included in the study following an
index episode of UTI (cystitis or acute pyelone-
phritis), irrespective of any history of recurrent
UTI. Women with renal or hepatic insufﬁciency,
and those receiving immunosuppressive therapy,
were excluded. The patients were followed clinic-
ally for at least 6 months, with urine cultures
every month. Urine samples were analysed in the
Clinical Microbiology Laboratory of the Hospital
Clinic, Barcelona, Spain. Eighty urine samples
positive for E. coli were included in this study.
Clinical variables recorded were: presence of
urinary incontinence; diabetes mellitus; indwell-
ing urethral catheter; renal insufﬁciency and
menopause; history of renal colic; urinary tract
abnormalities; previous UTI or urinary instru-
mentation; and exposure to antibiotics in the 3-
month period before the index infection. Urinary
tract abnormalities included bladder diverticuli,
cystocele, congenital malformations, stones and
renal cyst, as well as functional disorders such as
neurogenic bladder and vesicoureteral reﬂux.
The UPEC isolates collected from each patient
were analysed by repetitive extragenic palindro-
mic (REP)-PCR [3] and pulsed-ﬁeld gel electro-
phoresis of chromosomal DNA digested with XbaI
[4] to distinguish between re-infection and relapse.
Isolates with the same REP-PCR and pulsed-ﬁeld
gel electrophoresis ﬁngerprint patterns were con-
sidered to be the same strain. Virulence factors
were detected by PCR using gene-speciﬁc primers
[5] for haemolysin (hlyA), cytotoxic necrotising
factor-1 (cnf1), toxin autotransporter (sat), type 1
ﬁmbriae (ﬁmA), yersiniabactin (fyuA), aerobactin
(aer), S-ﬁmbriae (sfaS), P-ﬁmbriae (papA, C, G, EF
and prs) and Ag43 (ﬂu). Detection of bioﬁlm
production was based on a protocol described
Corresponding author and reprint requests: J. Vila, Depart-
ment of Microbiology, Hospital Clinic of Barcelona, Villarroel
170, 08036 Barcelona, Spain
E-mail: jvila@ub.edu
1034 Clinical Microbiology and Infection, Volume 12 Number 10, October 2006
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 1021–1045
previously [6]. The strains were grown overnight
in Luria–Bertani broth [7] at 37Cwithout shaking.
A 1.25-lL aliquot of an overnight culture was then
subcultured in 125 lL of M63 medium [7] con-
taining Luria–Bertani broth 1% v ⁄v in a well of a
polystyrene microtitre plate and incubated at 30C
overnight without shaking. A 1.25-lL of each
culture was then subcultured in 125 lL of M63
medium in a new polystyrenemicrotitre plate, and
re-incubated as described above. After 24 h, the
culture was removed from the plate and the
bioﬁlm was stained with 175 lL of crystal violet
for 1 min, washedwith phosphate-buffered saline,
and air-dried for c. 1 h. The retained stain was
solubilised in dimethylsulphoxide and the absorb-
ance was measured at 550 nm. A strain was
considered to be positive for bioﬁlm production
when the absorbance was greater than four-fold
the value for a control well without bacteria.
Proportions and means were compared using
the chi-square test and t-test. Logistic regression
was used to identify factors associated independ-
ently with relapse or re-infection. Two logistic
models were constructed: the ﬁrst, not including
clinical characteristics, in which the entire collec-
tion of E. coli strains was considered; and the
second, including clinical characteristics, in which
only the isolate causing the index episode of UTI
was considered.
During the study period, 80 unrelated E. coli
strains were collected from 43 females with recur-
rent UTI. Twenty-four patients had the sameE. coli
strain involved in at least one recurrent episode,
while 19 patients were infected by different E. coli
strains in each episode. Hence, 27 E. coli strains
were considered to cause relapse, and 53 were
categorised as causing re-infection. The mean age
of the patients was 48.3 ± 20.5 (range 19–89) years,
and 19 (44%) were post-menopausal. Twenty-
seven (63%) patients had at least one episode of
symptomatic UTI before enrolment in the study,
six (14%) had a history of renal colic, two (5%) had
been subject to urinary instrumentation, 16 (37%)
had a urinary tract abnormality, 22 (51%) had
some degree of incontinence, and four (9%) suf-
fered from diabetes mellitus. Thirty-three (77%)
patients had been exposed to antibiotics within
3 months of the index UTI, but none had renal
insufﬁciency or an indwelling urethral catheter.
The prevalence of in-vitro bioﬁlm formation
and virulence factors among strains causing
relapse and re-infection is shown in Table 1.
Three characteristics were signiﬁcantly more
frequent among strains causing relapses, namely
in-vitro bioﬁlm formation (p 0.005), the presence
of a yersiniabactin (fyu) gene and the presence of
an aerobactin (aer) gene (both p 0.04). Logistic
regression selected only bioﬁlm formation
(OR 4.96, 95% CI 1.65–14.9) and the presence of
a yersiniabactin gene (OR 3.6, 95% CI 1.18–11) as
factors that were associated independently with
strains involved in relapse.
When the analysis was restricted to the strains
involved in the index episode of UTI, again only
in-vitro bioﬁlm production (OR 11.4, 95% CI 2–
64.6) and the presence of a yersiniabactin gene
(OR 6.37, 95% CI 1.05–38.7) were associated inde-
pendently with relapse. In this respect, none of
the patient characteristics seemed to be important.
Recurrent UTIs are common among young,
healthy women, despite the fact that they gen-
erally have anatomically and physiologically
normal urinary tracts [8]. The data from the
present study indicate that the only factors
associated consistently with UTI relapse in
women are of microbial origin, i.e., the capacity
to form bioﬁlm in vitro and the presence of a
gene for yersiniabactin. Recurrence has been
associated previously with several virulence
determinants present in UPEC, and with beha-
vioural or other factors that facilitate vaginal
colonisation or entry of colonising uropathogens
into the bladder. However, Mulvey et al. [9]
demonstrated that uropathogens can persist
within the bladder tissue in underlying epithelial
cells and may be a source of recurrent UTI.
Anderson et al. [10] observed that intracellular
bacteria mature into bioﬁlms, creating pod-like
bulges on the bladder surface. This bacterial
structural organisation may explain the persist-
Table 1. Distribution of virulence characteristics among
Escherichia coli isolates causing relapse or re-infection
Characteristic
Relapse (n = 27)
No. (%)
Re-infection (n = 53)
No. (%) p
Bioﬁlm-positive 20 (74) 22 (42) 0.005
ﬂu 15 (56) 32 (60) 0.67
hlyA 7 (26) 19 (36) 0.37
cnf1 5 (19) 13 (25) 0.54
sat1 8 (30) 13 (25) 0.62
ﬁmA 24 (89) 47 (89) 0.97
fyu 20 (74) 27 (51) 0.04
aer 20 (74) 27 (51) 0.04
sfaS 9 (33) 11 (21) 0.21
papA 10 (37) 21 (40) 0.8
papC 13 (48) 24 (45) 0.8
papG 7 (26) 17 (32) 0.6
papEF 14 (52) 22 (42) 0.37
prs 7 (26) 8 (15) 0.3
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ence of bladder infections despite robust host
defences. Yersiniabactin and aerobactin, two viru-
lence factors related to iron-uptake systems, have
also been associated with relapse [11]; the present
data conﬁrmed these observations, which could be
related to the need of the bacteria to capture iron
for growth in a stressful environment. However,
bioﬁlm productionmay be the key determinant for
the persistence of UPEC in either the vaginal
reservoir, the bladder epithelial cells or both. An
in-vitro bioﬁlm assay could therefore be useful in
clinical practice to select patients who may require
a therapeutic approach directed at erradicating
persistent bioﬁlm-forming E. coli strains in order
to prevent subsequent relapses.
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ABSTRACT
In total, 150 methicillin-resistant Staphylococcus
aureus (MRSA) isolates collected during 2002 from
a general Belgian hospital were phage-typed at
routine test dilution · 100. The majority (45%)
belonged to phage group (J)*, while 10% were
classiﬁed as a new phage type 29 ⁄ (42E) ⁄
54 ⁄ (D11)*. The isolates belonging to this new type
carried the aac(6¢)-aph(2¢¢) and the aph(3¢) amino-
glycoside resistance genes and showed high-level
resistance to oxacillin. Molecular typing revealed
that they belonged to the multiresistant clonal
pulsed-ﬁeld gel electrophoresis (PFGE) type D8.
PFGE group D, characterised as genotype ST228-
MRSA-I, has been present in Belgian hospitals
since 1999.
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